HAMILTON, ON, Sept. 4, 2026 /PRNewswire/ — Atom Vie Global Radiopharma (Atom Vie), a prominent player in the radiopharmaceutical industry and a leading Contract Development and Manufacturing Organization (CDMO), has officially opened its new cutting-edge manufacturing facility located at 10 Aeropark Boulevard in Hamilton, Ontario. This milestone signifies an important step in Atom Vie’s journey to turn clinical success into effective therapies for patients around the globe.
A unique success story, Atom Vie originated from the Centre for Probe Development and Commercialization (CPDC), which is part of Mc Master University aimed at enhancing Canada’s role in radiopharmaceutical innovation and production. Currently, Atom Vie employs a growing team of skilled professionals and aims to have over 200 employees by late 2026 as operations expand at this new site.
Drawing on over ten years of experience along with recognized expertise in process and analytical method development, Atom Vie has assisted more than 70 clinical development programs and technology transfers. They have produced over 1,000 c GMP batches and supplied more than 4,400 c GMP doses to patients across 28 countries on six continents with a delivery success rate surpassing 99%. With this latest facility, Atom Vie is set up well to increase production alongside its partners from clinical trials through to commercial manufacture.
“This Grand Opening represents the next chapter of Atom Vie’s journey and a proud milestone for Canadian innovation in nuclear medicine,” said Bruno Paquin, Chief Executive Officer of Atom Vie. “Our new purpose-built facility amplifies a proven track record of reliable global delivery and deep scientific expertise, enabling us to support the development and commercialization of our partners’ pipelines. Above all, it advances our purpose of transforming patients’ lives by delivering high-quality radiopharmaceuticals to those who need them all around the world.”
“Atom Vie’s new facility inauguration reflects the discipline and dedication of the Atom Vie team and the confidence of the partners who have supported our growth,” said Kevin Mc Neill, Chairman of Atom Vie’s Board of Directors. “This facility continues Atom Vie’s status as a leading radiopharmaceutical CDMO now built at commercial scale to serve partners with the reliability that field requires.”
The Grand Opening celebration welcomed government representatives, clients, partners, and members from within the radiopharmaceutical community for tours showcasing how Atom Vie’s expertise contributes to delivering advanced precision cancer therapies globally.
About Atom Vie Global Radiopharma (Atom Vie)
Atom Vie is a globally recognized CDMO that provides an extensive array of scientific, technical, regulatory quality services combined with specialized infrastructure for developing radiopharmaceuticals from phase I through phase III clinical studies up until commercialization. Presently serving international clients conducting clinical studies across over 28 countries worldwide. For additional details visit our website https://www. atomvie. com.
SOURCE: Atom Vie Global Radiopharma Inc.
Source link
Source link
